Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of EYPT is 35 and suggests 92% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell